Pharma BD Deal Intelligence

Jazz Pharmaceuticals plc / EUSA Pharma

2012 · Acquisition/Merger · $700M · Complete

Announcement Sentiment

Strongly positive

Jazz Pharmaceuticals acquired EUSA Pharma for $650M cash plus up to $50M contingent milestone. Brought Erwinaze (key US ALL salvage therapy) and EUSA's specialty commercial infrastructure. Expected $210-230M revenue contribution in 2013.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Apr 26, 2012
Closed Jun 12, 2012
Deal value $700M
Deal type Acquisition/Merger
Therapeutic area Acute lymphoblastic leukemia (ALL) hypersensitivity to E. coli asparaginase
Indications Acute lymphoblastic leukemia (ALL) hypersensitivity to E. coli asparaginase
Key assets Erwinaze (asparaginase Erwinia chrysanthemi)
Mechanism Bacterial asparaginase enzyme

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals